Natus Medical Inc (NASDAQ:BABY) – Analysts at William Blair lowered their FY2018 earnings per share estimates for shares of Natus Medical in a research report issued to clients and investors on Wednesday. William Blair analyst B. Weinstein now forecasts that the medical equipment provider will post earnings per share of $1.63 for the year, down from their previous estimate of $2.08. William Blair has a “Market Perform” rating on the stock.
Several other analysts have also recently weighed in on the stock. Zacks Investment Research upgraded shares of Natus Medical from a “hold” rating to a “buy” rating and set a $45.00 price objective on the stock in a research report on Tuesday, October 24th. BidaskClub cut shares of Natus Medical from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th. Finally, Benchmark restated a “buy” rating and set a $49.00 price objective (down previously from $55.00) on shares of Natus Medical in a research report on Tuesday, January 16th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $47.00.
Natus Medical (NASDAQ:BABY) last posted its earnings results on Wednesday, February 7th. The medical equipment provider reported $0.42 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.54 by ($0.12). Natus Medical had a positive return on equity of 11.36% and a negative net margin of 4.05%. The firm had revenue of $131.40 million during the quarter, compared to analysts’ expectations of $131.38 million. During the same quarter in the prior year, the company earned $0.51 earnings per share. The business’s revenue for the quarter was up 22.0% compared to the same quarter last year.
Several institutional investors have recently bought and sold shares of the company. Alliancebernstein L.P. raised its position in shares of Natus Medical by 2.3% during the 2nd quarter. Alliancebernstein L.P. now owns 53,756 shares of the medical equipment provider’s stock valued at $2,005,000 after buying an additional 1,190 shares in the last quarter. American International Group Inc. raised its position in Natus Medical by 5.7% in the 3rd quarter. American International Group Inc. now owns 25,767 shares of the medical equipment provider’s stock worth $966,000 after purchasing an additional 1,398 shares during the period. Ladenburg Thalmann Financial Services Inc. raised its position in Natus Medical by 11.5% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 14,044 shares of the medical equipment provider’s stock worth $527,000 after purchasing an additional 1,452 shares during the period. Rhumbline Advisers raised its position in Natus Medical by 2.5% in the 3rd quarter. Rhumbline Advisers now owns 67,065 shares of the medical equipment provider’s stock worth $2,515,000 after purchasing an additional 1,620 shares during the period. Finally, Flinton Capital Management LLC raised its position in Natus Medical by 82.0% in the 2nd quarter. Flinton Capital Management LLC now owns 3,774 shares of the medical equipment provider’s stock worth $141,000 after purchasing an additional 1,700 shares during the period. Hedge funds and other institutional investors own 99.64% of the company’s stock.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.